Tag archive for ‘COSMIC-HF trial in heart failure’
Cytokinetics: I Predict Amgen Will Proceed to Phase 3 Trials with Omecamtiv Mecarbil (CYTK, Buy, $10.82)
Investment Thesis I continue with my long standing buy recommendation on the stock. I think a Buy at this level is justified by the prospects for omecamtiv mecarbil alone even if tirasemtiv were to fail in its phase 3 trial in ALS and CK-107 is not progressed in spinal muscular atrophy. Of course, I think […]